- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01794481
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- The University of Michigan Comprehensive Cancer Center
-
Ann Arbor, Michigan, United States, 48105
- Veterans Affairs (VA) Ann Arbor Healthcare System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with American Joint Committee on Cancer (AJCC) stage II-IV head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with radiotherapy (with or without chemotherapy or targeted agents), and who are capable of understanding and adhering to the protocol requirements.
- Patients must be willing to comply with the study procedures and visits
Exclusion Criteria:
- Active cardiopulmonary disease
- Substantial dementia (based on Folstein Mini Mental State Examination <24 out of 30)
- Acute medical conditions, such as acute flare-up of joint condition or infection
- Participants must not be actively receiving physical therapy, at time of enrollment, or actively exercising 2 or more hours a day, with the intent to continue that regimen
- Patients refusing a percutaneous endoscopic gastrotomy (PEG) Tube needed for nutrition, as determined necessary by treating physician
- Patients are actively being treated for another cancer at the time of enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed.
As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
|
|
|
Experimental: Resistance Exercise Training
If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy. There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique. |
If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy. There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of resistance exercise training (RET) versus usual care (UC) on the preservation of lean body mass.
Time Frame: 14 weeks
|
Lean body mass will be analyzed at baseline, 3, 5, and 7-weeks (representing the last week of cancer treatment and end of on-site RET), 11-weeks (first clinic follow-up) and 14-weeks (second clinic follow-up and end of home-based RET program) for patients on both arms of the study.
|
14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of resistance exercise training (RET) versus usual care (UC) on the preservation of muscle strength.
Time Frame: 14 weeks
|
Upper and lower body strength will be analyzed at baseline, 3, 5, and 7-weeks (representing the last week of cancer treatment and end of on-site RET), 11-weeks (first clinic follow-up) and 14-weeks (second clinic follow-up and end of home-based RET program) for patients on both arms of the study.
|
14 weeks
|
|
The effect of resistance exercise training (RET) versus usual care (UC) on six minute walk distance
Time Frame: 14 weeks
|
The distance walked in six minutes at baseline will be compared to the distance walked at 14 weeks for both groups.
These finding will then be compared between the groups.
|
14 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shruti Jolly, MD, University of Michigan Rogel Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011.070
- HUM 33897 (Other Identifier: University of Michigan IRBMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
University of Michigan Rogel Cancer CenterSummit TherapeuticsRecruitingAdvanced Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma | Stage II Head and Neck Cutaneous Squamous Cell Carcinoma | Stage III Head and Neck Cutaneous Squamous Cell Carcinoma | Stage IV Head and Neck Cutaneous Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Washington University School of MedicineMerck Sharp & Dohme LLCCompletedHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
Bristol-Myers SquibbCompletedSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Medical College of WisconsinCompletedResectable Head and Neck Squamous Cell CarcinomaUnited States
-
VLP TherapeuticsStanford UniversityRecruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Solid Tumors | Head and Neck Squamous Cell Cancer | Head Neck Cancer | Oral Cavity Carcinoma | HNSCC | Oral Cavity | Squamous Cell Carcinoma, Head And Neck | Head and Neck Cancers- Squamous Cell | Squamous Cell Head and Neck Carcinoma | SCCHN and other conditionsUnited States
-
Mayo ClinicRecruitingResectable Head and Neck Squamous Cell Carcinoma | HPV-Negative Squamous Cell Carcinoma | Resectable Head and Neck Squamous-cell Carcinoma | Human Papillomavirus-Negative Neck Squamous Cell Carcinoma | Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell CarcinomaUnited States
Clinical Trials on Resistance Exercise Training (RET)
-
University of NottinghamActive, not recruiting
-
University of NottinghamUniversity of BirminghamUnknownOverweight and ObesityUnited Kingdom
-
Bangor UniversityBetsi Cadwaladr University Health BoardCompletedChronic Kidney DiseaseUnited Kingdom
-
Florida State UniversityNutrisystem, Inc.CompletedHypertension | Obesity | Pre-hypertensionUnited States
-
Beijing Sport UniversityRecruitingHypertension | Cognitive FunctionChina
-
University of New MexicoActive, not recruiting
-
University of New MexicoActive, not recruitingPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)United States
-
Mehmet Akif Ersoy UniversityKarabuk UniversityCompleted
-
University of HoustonTerminated
-
Riphah International UniversityCompletedChronic Obstructive Pulmonary DiseasePakistan